Immune Checkpoint Inhibitor-Induced Primary Adrenal Insufficiency: A Case Report

Overview

Journal Clin Pract Cases Emerg Med

Specialty Emergency Medicine

Date 2024 Dec 20

PMID 39704571

Authors

Rahul Gupta

Cary Lubkin

Affiliations

Soon will be listed here.

Abstract

Introduction: One of the less common and more life-threatening etiologies of adrenal insufficiency is immune checkpoint inhibitor (ICI)-induced primary adrenal insufficiency (PAI). Patients typically present with fatigue, malaise, and nausea and are treated empirically with hydrocortisone.

Case Report: We present the case of a 59-year-old female who presented with hypotension, which initially was thought to be due to hypovolemia or medication-related, but was ultimately found to have PAI.

Conclusion: This case highlights the importance of early detection of ICI-induced primary adrenal insufficiency, given its associated morbidity and mortality and its incidence in patients with a history of immunotherapy.

References

Salinas C, Renner A, Rojas C, Samtani S, Burotto M . Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature. Case Rep Oncol. 2020; 13(2):621-626. PMC: 7315192. DOI: 10.1159/000507652. View

Stelmachowska-Banas M, Czajka-Oraniec I . Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect. 2020; 9(10):R207-R228. PMC: 7576644. DOI: 10.1530/EC-20-0342. View

Paepegaey A, Lheure C, Ratour C, Lethielleux G, Clerc J, Bertherat J . Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. J Endocr Soc. 2017; 1(6):646-649. PMC: 5686573. DOI: 10.1210/js.2017-00170. View

Martella S, Lucas M, Porcu M, Perra L, Denaro N, Pretta A . Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol. 2023; 50(6):144-148. DOI: 10.1053/j.seminoncol.2023.11.003. View

Tan M, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern M, Shen L . Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019; 5:1. PMC: 6343255. DOI: 10.1186/s40842-018-0073-4. View

Cherry G . Immune Checkpoint Inhibitor-Related Adrenal Insufficiency. Semin Oncol Nurs. 2021; 37(2):151131. DOI: 10.1016/j.soncn.2021.151131. View

Grouthier V, Lebrun-Vignes B, Moey M, Johnson D, Moslehi J, Salem J . Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Oncologist. 2020; 25(8):696-701. PMC: 7418341. DOI: 10.1634/theoncologist.2019-0555. View

Barroso-Sousa R, Barry W, Garrido-Castro A, Hodi F, Min L, Krop I . Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2017; 4(2):173-182. PMC: 5838579. DOI: 10.1001/jamaoncol.2017.3064. View

Wright J, Powers A, Johnson D . Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021; 17(7):389-399. PMC: 8769055. DOI: 10.1038/s41574-021-00484-3. View

10.

Cukier P, Santini F, Scaranti M, Hoff A . Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017; 24(12):T331-T347. DOI: 10.1530/ERC-17-0358. View

11.

Cui K, Wang Z, Zhang Q, Zhang X . Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study. Ann Transl Med. 2022; 10(5):251. PMC: 8987884. DOI: 10.21037/atm-21-7006. View

12.

Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X . Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS. J Endocrinol Invest. 2022; 45(11):2131-2137. PMC: 9525402. DOI: 10.1007/s40618-022-01845-z. View

13.

Shi Y, Shen M, Zheng X, Yang T . Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management. Endocr Pract. 2021; 27(2):165-169. DOI: 10.1016/j.eprac.2020.09.016. View